Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;37(2):127-133.
doi: 10.37201/req/143.2023. Epub 2023 Dec 22.

Safety of fluoroquinolones

J Barberán  1 , A de la Cuerda, M I Tejeda González, A López Aparicio, C Monfort Vinuesa, A Ramos Sánchez, L C Barberán
Affiliations
Review

Safety of fluoroquinolones

J Barberán et al. Rev Esp Quimioter. 2024 Apr.

Abstract
in English, Spanish

Fluoroquinolones (FQs) are one of the most commonly prescribed classes of antibiotics. Although they were initially well tolerated in randomized clinical trials, subsequent epidemiological studies have reported an increased risk of threatening, severe, long-lasting, disabling and irreversible adverse effects (AEs), related to neurotoxicity and collagen degradation, such as tendonitis, Achilles tendon rupture, aortic aneurysm, and retinal detachment. This article reviews the main potentially threatening AEs, the alarms issued by regulatory agencies and therapeutic alternatives.

Las fluoroquinolonas son una de las clases de antibióticos más prescritas. Aunque inicialmente fueron bien toleradas en ensayos clínicos aleatorizados, estudios epidemiológicos posteriores han informado de un mayor riesgo de efectos adversos efectos adversos amenazantes, graves, duraderos, incapacitantes e irreversibles, relacionados con la neurotoxicidad y la degradación del colágeno, como tendinitis, rotura del tendón de Aquiles, aneurisma aórtico y desprendimiento de retina. Este artículo repasa los principales efectos adversos potencialmente amenazadores, las alarmas emitidas por las agencias reguladoras y las alternativas terapéuticas.

Keywords: Fluoroquinolones; adverse effects; aortic aneurism; dysglycemia; neuropathy; tendon rupture.

PubMed Disclaimer

Conflict of interest statement

JB have received honoraria for lectures and advisory boards for Pfizer, Wyeth, Merck, Angelini, Menarini, Meiji Pharma Spain, Shionogi and Gilead. Rest of authors declare no conflict of interest.

References

    1. Ball, P. Quinolone Generations: Natural History or Natural Selection? J Antimicrob Chemother. 2000, 46, 17–24. 10.1093/oxfordjournals.jac.a020889 - DOI - PubMed
    1. Rusu A, Munteanu AC, Arbanas EM, Uivarosi V. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?. Pharmaceutics 2023, 15, 804. 10.3390/pharmaceutics15030804 - DOI - PMC - PubMed
    1. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980–2009. J Law Med Ethics 2013; 41:688–696. 10.1111/jlme.12079 - DOI - PubMed
    1. Chan EW, Liu KQL, Chui CSL, Sing CW, Wong LYL, Wong ICK. Adverse drug reactions–examples of detection of rare events using databases. Br J Clin Pharmacol 2015; 80(4):855-61. 10.1111/bcp.12474 - DOI - PMC - PubMed
    1. Tandan M, Cormican M, Vellinga A. Adverse events of ßuoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Inter J Antimicrob Agents 2018, 10.1016/j.ijantimicag.2018.04.014. - DOI - PubMed

MeSH terms